Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection.
OBJECTIVE
To analyze the correlation between CD14 rs2569190/C-159T single nucleotide polymorphism (SNP) and disease progression in chronic hepatitis C.


METHODS
Liver biopsy specimens from a total of 137 and 349 patients with chronic hepatitis C were separately evaluated with respect to necroinflammatory activity (grading) and architectural changes (staging). In one group, further histological lesions characteristic for hepatitis C, hepatitis C virus subtypes, and biochemical parameters of liver disease were also investigated. Samples of genomic DNA were genotyped for the respective SNP by 5'-nuclease assays using fluorescent dye-labeled allele-specific probes.


RESULTS
Genotype distribution did not deviate from the Hardy-Weinberg equilibrium. In the first group, patients homozygous for the variant allele T were found to be younger than C allele carriers (39.6 +/- 12.5 vs 45.7 +/- 11.5, P = 0.008). Among the histological lesions studied, portal lymphoid aggregates were more frequently observed among TT homozygotes than among C carriers (21/37 vs 32/100, P = 0.008). The presence of portal lymphoid aggregates was closely correlated with hepatic inflammation (P = 0.003) and with bile duct damage (P < 0.001). The degree of fibrosis, in contrast, was not found to be related to the CD14 gene C-159T polymorphism.


CONCLUSIONS
The data suggest a possible relationship between CD14 C-159T polymorphism and the formation of portal lymphoid aggregates, but not liver fibrosis progression in chronic hepatitis C.
Askar
Eva
E
Department of Gastroenterology and Endocrinology, University Medical Center, Georg-August-University, Robert-Koch-Strasse 40, D-37075 Goettingen, Germany.
Ramadori
Giuliano
G
Mihm
Sabine
S
D000328:Adult; D018450:Disease Progression; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000235:genetics*; D008103:Liver Cirrhosis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011971:Receptors, Immunologic / Q000235:genetics*
D018950:Lipopolysaccharide Receptors; D011971:Receptors, Immunologic; C048071:endotoxin receptor
J Immunol. 2001 Nov 15;167(10):5838-44
11698458
Clin Microbiol Rev. 2008 Jan;21(1):13-25
18202435
Am J Gastroenterol. 1999 Apr;94(4):1006-11
10201474
Hepatology. 2007 Aug;46(2):297-306
17461418
Hepatology. 2001 May;33(5):1148-53
11343243
J Clin Pathol. 1996 Jun;49(6):465-9
8763259
Immunity. 2006 Feb;24(2):153-63
16473828
World J Gastroenterol. 2006 Nov 14;12(42):6756-65
17106922
J Endotoxin Res. 2005;11(4):225-9
16176659
Hepatology. 2003 Sep;38(3):543-4
12939578
Clin Exp Allergy. 2008 Dec;38(12):1929-34
19037967
Scand J Gastroenterol. 2008;43(5):584-92
18415752
Lancet Infect Dis. 2005 Sep;5(9):558-67
16122679
World J Gastroenterol. 2005 Oct 14;11(38):6031-7
16273620
Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G256-65
12121871
Hepatology. 1995 Aug;22(2):389-94
7635405
Lancet. 1997 Mar 22;349(9055):825-32
9121257
Gastroenterology. 2006 May;130(6):1886-900
16697751
Nat Genet. 2003 Feb;33(2):177-82
12524541
Hepatology. 1997 Mar;25(3):735-9
9049227
Eur J Gastroenterol Hepatol. 2006 Sep;18(9):991-7
16894313
J Med Virol. 2009 Jul;81(7):1204-11
19475618
Dig Dis Sci. 1996 Jun;41(6):1256-64
8654161
Hepatology. 2003 May;37(5):1043-55
12717385
Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
12407575
Hepatology. 1999 Jul;30(1):143-50
10385650
Hepatology. 1994 Jun;19(6):1513-20
8188183
Alcohol Clin Exp Res. 2005 Jul;29(7):1206-13
16046876
Springer Semin Immunopathol. 1997;19(1):99-110
9266634
Immunology. 2004 Oct;113(2):153-62
15379975
Hepatology. 2003 Mar;37(3):493-503
12601343